版本:
中国

BRIEF-Novartis: CAR-T therapy CTL119 combo had high response rate in CLL

May 31 Novartis Ag

* Novartis says car-t cell therapy ctl119 combined with ibrutinib in pilot study shows high rate of responses in cll patients Source text for Eikon: Further company coverage: (Reporting by John Miller)

我们的标准: 汤森路透“信任原则

更多 瑞士市场报道

热门文章

编辑推荐

文章推荐